Sign In
Buy FDMT
$9.53
+0.260 (+2.80%)
At Close: Jun 03, 2026
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
07:05am, Friday, 30'th Apr 2021
EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther
- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24 th Annual Meeting
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
04:02pm, Thursday, 25'th Mar 2021
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
08:03am, Tuesday, 09'th Mar 2021
EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther
Andreas Halvorsen Jumps Into 2 New Biotech Companies
05:24pm, Tuesday, 22'nd Dec 2020
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a P
